A Phase 1c Study Investigating the SAfety and TolErability of a LysyL Oxidase InhibiTor (PXS-6302) in the amElioration of Keloids

Keloids are raised, overgrown scars that form when the body produces too much scar tissue — often after an injury, surgery, or skin irritation. They can be itchy, painful, and distressing, and current treatments don't always work well. This Phase 1 study is testing a new topical cream called PXS-6302 to see if it is safe and whether it can reduce the size and discomfort of keloids when applied directly to the skin for three months. Up to 20 participants will take part at a single centre in Western Australia. Everyone in the study will receive the active cream on their keloid, and if they have more than one keloid, a placebo cream will be used on the others for comparison purposes. Researchers will monitor any side effects and measure changes in keloid size and symptoms over time. You may be eligible if you are aged 18 to 60 and have an active keloid that has been present for at least four weeks and measures between 5 and 25 square centimetres. You must not have keloids on your ears or have received any keloid treatment in the last three months. Pregnant or breastfeeding women, and people with significant health conditions, are not eligible.